AMEDAMEDISYS INC


$ 96.88 $ 0.00 (0 %)    

Monday, 16-Sep-2024 15:58:57 EDT
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ na
$ 96.76
$ 96.78 x 200
-- x --
$ 96.61 - $ 97.08
$ 89.55 - $ 98.95
321,648
na
3.17B
$ 0.59
$ 34.49
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deutsche-bank-downgrades-amedisys-to-hold-maintains-price-target-to-101

Deutsche Bank analyst Justin Bowers downgrades Amedisys (NASDAQ:AMED) from Buy to Hold and maintains the price target from $...

 cantor-fitzgerald-reiterates-neutral-on-amedisys-maintains-101-price-target

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

 amedisys-q2-eps-132-beats-118-estimate-sales-59119m-beat-57882m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.18 by 11....

 william-blair-downgrades-amedisys-to-market-perform

William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:AMED) from Outperform to Market Perform.

 cantor-fitzgerald-reiterates-neutral-on-amedisys-maintains-101-price-target

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

 amedisys-q1-2024-adj-eps-103-beats-102-estimate-sales-571400m-beat-565380m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.9...

 raymond-james-maintains-market-perform-on-amedisysto-market-perform

Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) from Market Perform to Market Perform.

 rbc-capital-maintains-outperform-on-amedisys-raises-price-target-to-100

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $97 to $...

 amedisys-q4-2023-adj-eps-0940-misses-1030-estimate-sales-570800m-beat-567713m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by...

 amedisys-q4-2023-adj-eps-094-misses-103-estimate-sales-57080m-beat-56771m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8...

 amedisys-offers-molecular-testing-for-rapid-and-accurate-infection-diagnosis-in-collaboration-with-patient-choice-laboratories

Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering adva...

 amedisys-q3-adj-eps-098-misses-108-estimate-sales-55620m-miss-56127m-estimate

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9...

 cantor-fitzgerald-maintains-neutral-on-amedisys-raises-price-target-to-101

Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $100 ...

 td-cowen-maintains-market-perform-on-amedisys-raises-price-target-to-101

TD Cowen analyst Gary Taylor maintains Amedisys (NASDAQ:AMED) with a Market Perform and raises the price target from $84 to ...

 credit-suisse-reiterates-neutral-on-amedisys-maintains-101-price-target

Credit Suisse analyst Jonathan Yong reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

 amedisys-q2-adj-eps-137-beats-109-estimate-sales-55300m-miss-56820m-estimate

Amedisys (NASDAQ:AMED) reported quarterly adj earnings of $1.37 per share which beat the analyst consensus estimate of $1.09 by...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION